Aanchal 
The CDSCO Rules for New Drugs 2025 have officially come into effect, marking a major reform in India’s pharmaceutical regulatory framework. The Central Drugs Standard Control Organisation (CDSCO) has overhauled its drug approval process to reduce delays, promote innovation, and ensure faster availability of life-saving medications to the Indian population. The government has introduced automated … Read more
The Pharma Manufacturing Hubs 2025 initiative is transforming India’s pharmaceutical production landscape with state-of-the-art industrial clusters across the country. Under the Atmanirbhar Bharat and Pharma Vision 2047 programmes, the Government of India has announced the operational rollout of several new pharmaceutical manufacturing hubs aimed at boosting exports, generating employment, and strengthening drug security. These dedicated … Read more
The Indian Pharma Bulk Drug Import 2025 landscape reveals some critical trends in sourcing, cost dynamics, and dependency on global suppliers. Despite India being a global leader in generic drug manufacturing, a significant portion of Active Pharmaceutical Ingredients (APIs) and bulk drugs are still imported—especially from countries like China. In 2025, bulk drug imports have … Read more
The Government of India has officially launched the Pharma Innovation Fund India 2025, allocating ₹1500 crore to fuel pharmaceutical research and development across the country. This strategic initiative is aimed at boosting India’s self-reliance in drug discovery, biotechnology, and formulation sciences. As a part of the Department of Pharmaceuticals’ Vision 2047 roadmap, this fund is … Read more
The Government of India has officially announced a significant change in API Import Duty India 2025, effective from August. This move is a part of the larger policy to promote domestic manufacturing of Active Pharmaceutical Ingredients (APIs) under the Atmanirbhar Bharat initiative. The updated duty structure introduces increased import tariffs on over 40 high-demand APIs, … Read more
The Government of India has released a major update in June 2025 regarding its ambitious Bulk Drug Park Scheme, a cornerstone of India’s pharmaceutical self-reliance strategy. Under this scheme, the government has sanctioned fresh subsidy allocations to three key states to accelerate the production of Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and intermediates. … Read more
The Indian government has officially released the NLEM List 2025, marking a crucial development in the country’s healthcare affordability and accessibility. The National List of Essential Medicines (NLEM) is updated by the Ministry of Health and Family Welfare to reflect current healthcare needs and disease patterns. These are life-saving medicines that must be available at … Read more
India continues to solidify its position as the pharmacy of the world with remarkable progress in Pharma Export India 2025. The country has seen a sharp rise in exports of pharmaceutical formulations, bulk drugs (APIs), and biotechnology products, crossing new trade milestones in global markets. According to the Ministry of Commerce and Industry, India’s pharmaceutical … Read more
The government of India has released the Jan Aushadhi Medicine List 2025, bringing updated prices and expanded availability of essential generic medicines across the country. Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the Ministry of Chemicals and Fertilizers continues its commitment to provide affordable healthcare by offering quality medicines at substantially reduced rates through … Read more